How Do Cancer Cells Evade the Immune System?
June 16, 2026Core framework and Diagram What Is Tumor Immunology?
July 6, 2026
1 minuete Read
What Is Tumor Immunology?
Cancer is not only a story of cells going out of control — it's the immune system's long surrender
By the Editors 1-min read
You may have heard: every person generates cancer cells daily, but most people don't get cancer because the immune system clears them. That statement is largely correct — but it only tells the first half of the story.
The second half: some cancer cells learned how to make the immune system 'blind' to them, or to simply 'shut it down.' When that happens, tumors truly establish themselves.
Tumor immunology studies exactly this war between the immune system and cancer — how they meet, how they face off, how the immune system wins, and how cancer makes the immune system lose. Understanding this war is the starting point for understanding modern cancer immunotherapy.
KEY TAKEAWAYS
01
Tumor immunology reveals the second truth about cancer: cancer is not merely cellular loss of control, but the result of a long-term battle between the immune system and the tumor.
02
William Coley used infections to activate the immune system to treat tumors in the 1890s, a century ahead of the scientific explanation for immunotherapy—his intuition was correct, but it took a hundred years to understand the mechanism.
03
The approval of Ipilimumab in 2011 was a turning point: it proved for the first time that mobilizing the immune system (rather than directly killing tumor cells) could achieve durable anti-cancer effects.
04
Key players: NK cells (innate), CD8+ T cells (adaptive), dendritic cells (intelligence), and macrophages (dual-faced)—each plays a critical role in the cancer battle.
05
The logical advantages of immunotherapy—precise recognition, systemic coverage, and immune memory—are unattainable by chemotherapy and radiotherapy. Its limitations lie in the fact that not everyone responds, and it carries immune-related toxic side effects.
06
Directions for the next decade: personalized vaccines, CAR-T/CAR-NK, TME (tumor microenvironment) remodeling, and combination therapeutic strategies—each is built upon a profound understanding of immune evasion and the tumor microenvironment.
Read Next
